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ABSTRACT
Objectives: To describe the rationale, design and
methodology for a trial of three novel interventions
developed to improve sedation-analgesia quality in
adult intensive care units (ICUs).
Participants and Setting: 8 clusters, each a Scottish
ICU. All mechanically ventilated sedated patients were
potentially eligible for inclusion in data analysis.
Design: Cluster randomised design in 8 ICUs, with
ICUs randomised after 45 weeks baseline data
collection to implement one of four intervention
combinations: a web-based educational programme (2
ICUs); education plus regular sedation quality feedback
using process control charts (2 ICUs); education plus a
novel sedation monitoring technology (2 ICUs); or all
three interventions. ICUs measured sedation-analgesia
quality, relevant drug use and clinical outcomes,
during a 45-week preintervention and 45-week
postintervention period separated by an 8-week
implementation period. The intended sample size was
>100 patients per site per study period.
Main Outcome measures: The primary outcome
was the proportion of 12 h care periods with optimum
sedation-analgesia, defined as the absence of agitation,
unnecessary deep sedation, poor relaxation and poor
ventilator synchronisation. Secondary outcomes were
proportions of care periods with each of these four
components of optimum sedation and rates of
sedation-related adverse events. Sedative and analgesic
drug use, and ICU and hospital outcomes were also
measured.
Analytic approach: Multilevel generalised linear
regression mixed models will explore the effects of
each intervention taking clustering into account, and
adjusting for age, gender and APACHE II score.
Sedation-analgesia quality outcomes will be explored at
ICU level and individual patient level. A process
evaluation using mixed methods including quantitative
description of intervention implementation, focus
groups and direct observation will provide explanatory
information regarding any effects observed.
Conclusions: The DESIST study uses a novel design
to provide system-level evaluation of three contrasting
complex interventions on sedation-analgesia quality.
Recruitment is complete and analysis ongoing.
Trial registration number: NCT01634451.
INTRODUCTION
Most mechanically ventilated critically ill
patients require sedation and analgesia.
Avoidance of unnecessary deep sedation is a
priority in intensive care units (ICUs), because
this is associated with adverse outcomes such
as longer ICU stay, more ICU-acquired infec-
tions and, possibly, higher mortality.1–3
Strategies that promote lighter sedation can
improve these outcomes,4 but patient agitation
Strengths and limitations of this study
▪ This detailed description of the development and
design of the DESIST trial will facilitate better
understanding of the study results.
▪ The modified cluster design will efficiently enable
an exploration of the system level effects of three
contrasting interventions on sedation quality in
mechanically ventilated patients.
▪ The use of multilevel generalised linear regres-
sion mixed models will enable adjustment for
important intensive care unit and patient level
factors in the analysis to explore treatment
effects at system level.
▪ A detailed mixed methods process evaluation of
the complex interventions will enable a better
understanding of each intervention and any clin-
ical effects observed.
▪ Weaknesses include the potential for variability
in uptake and use of the interventions, and
limited study power for secondary outcomes
such as drug use and length of stay. The import-
ance of participation bias is also difficult to
assess in system-level quality improvement
research.
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can also compromise patient safety, and increase staff
workload and stress.5–7 Lighter sedation also potentially
exposes patients to pain and discomfort, which are widely
reported by ICU survivors.8–11 Optimum sedation is
patient speciﬁc, but the avoidance of deep sedation can be
considered while ensuring adequate management of pain
and agitation. The most effective system level approaches
for optimising all aspects of sedation within ICUs is uncer-
tain. Implementing and sustaining improvements in ICU
sedation quality is challenging.
We describe the rationale, design and methodology of
a quality improvement trial designed to evaluate the
effectiveness of three contrasting complex intervention
strategies. Each was developed to improve sedation
quality for ICU patients, but with differing underpinning
rationale. This trial is the central project in the
Development and Evaluation of Strategies to Improve
Sedation practice in InTensive care (DESIST) research
programme (ClinicalTrials.gov NCT01634451).
Underpinning research completed during the early part
of the research developed and validated the trial
outcome measures, and one of the interventions used in
the trial, and has been reported in detail separately.12
The trial has completed recruitment (December 2014),
and analysis and reporting is ongoing. This manuscript
provides a detailed description of the development of the
trial design and the methodological approach to analysis,
which will complement the reporting of the study ﬁnd-
ings. The DESIST research programme is funded by the
Chief Scientists Ofﬁce, Scotland; and through unre-
stricted research sponsorship from GE Healthcare.
STUDY OBJECTIVES
The primary objective of DESIST is to explore the effect-
iveness of three system-wide interventions on
sedation-analgesia quality in mechanically ventilated
ICU patients, and any interaction between the interven-
tions. The three interventions studied are:
1. A web-based modular educational resource, targeted
primarily at nursing staff, termed ‘DESIST education’.
2. Feedback of sedation quality at regular intervals using
process control methodology, termed ‘DESIST
process feedback’.
3. The introduction of a novel sedation monitoring
system into the ICU, the Responsiveness Index (RI),
which continuously monitors patient arousals by
facial electromyograph (fEMG) analysis, with the
intention of alerting staff to ‘unresponsive’ patients
who are at highest risk of deep sedation. This is
termed ‘DESIST responsiveness monitoring’.
Secondary objectives are to evaluate the effect of the
three interventions on: (1) the incidence of predeﬁned
sedation-related adverse events; (2) the use of intraven-
ous sedative analgesic and antipsychotic drugs; (3) the
duration of mechanical ventilation, ICU and hospital
stay; and (4) ICU and hospital mortality. In addition, data
will be collected to explore measures of patient experi-
ence, memories and traumatic experiences in the ICU.
A mixed methods design was considered most suited to
describing the trial outcomes. Speciﬁcally, mixed methods
for process evaluation of the intervention study will be
used to supplement the main quantitative outcomes.
STUDY OVERVIEW
The DESIST trial is the ﬁnal phase of a programme of
quality improvement work, undertaken in several stages.
Development and implementation of sedation quality
measurement tools
A systematic review found no single simple clinical tool
that could be systematically used to measure all aspects
of patient status in relation to sedation-analgesia, or to
deﬁne optimum sedation.13 Speciﬁcally, an outcome
measure was required that incorporated unnecessary
deep sedation, agitation and pain/discomfort, and
included information required to deﬁne a consistent
denominator for prevalence calculations.
In stage 1, a Sedation Quality Assessment Tool (SQAT)
was developed and validated for measuring
sedation-analgesia quality for each 12 h care period (typ-
ically an ICU nursing ‘shift’). This was termed a ‘DESIST
care period’. Other data recorded in the SQAT included
the concurrent use of mechanical ventilation; sedative,
analgesic and neuromuscular blocking drugs; the pres-
ence of clinical conditions that justify deep sedation; and
the requirement for therapies that may require deep sed-
ation. The validity and reliability of the SQAT tool are
reported separately.12 The SQAT is shown in ﬁgure 1.
In stage 2, the SQAT was progressively implemented
into routine practice in all the eight participating ICUs.
Once established with high completion rates by nursing
staff, we started enrolling patients into a preintervention
data collection period (see below). During this period
we used an iterative process with multiple members of
the research team to develop algorithms that used SQAT
data to classify patient status for each DESIST care
period in the following domains to a binary yes/no state:
(1) unnecessary deep sedation; (2) agitated; (3) poor
limb relaxation (a measure of pain/discomfort); and (4)
poor ventilator synchronisation. These four measures
were the most valid and reliable overall as metrics for
describing sedation quality.12 Importantly, we used SQAT
ﬁelds to censor episodes of deep sedation that were
potentially clinically indicated (for example: advanced
ventilation strategies, therapeutic hypothermia, brain
injury) and capture only unnecessary deep sedation
counts. SQAT ﬁelds also enabled relevant denominator
data to be captured, for example, ventilation status and
presence of coma despite not receiving sedatives, to
censure patients where appropriate during calculation
of sedation quality metrics. The outcome of this part of
the project was a list of quality measures that demon-
strated reliability, construct and face validity. The ﬁnal
measures chosen were:
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1. Proportion of DESIST care periods with patient
agitation
2. Proportion of DESIST care periods with excessive
sedation
3. Proportion of DESIST care periods with poor
relaxation
4. Proportion of DESIST care periods with poor ventila-
tor synchronisation
5. Proportion of DESIST care periods with optimum
sedation (optimum sedation was a DESIST care
period where neither patient agitation, excessive sed-
ation, poor relaxation, nor poor ventilator
Figure 1 The Sedation Quality Assessment Tool (SQAT) used to capture data for each 12 h period of nursing care during ICU
admission. ICU, intensive care unit.
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synchronisation were present, after censoring for rele-
vant clinical information).
This part of the DESIST research programme has
been reported separately.12
Assessing the impact of the quality improvement
interventions: general design
DESIST is a quality improvement trial. Our hypothesis is
that the interventions we developed will be used within
the ICUs to improve practice, which will translate into
improvements to sedation quality, measured using the
metrics developed for the trial. DESIST is an evaluation
of complex healthcare interventions and we expect any
effects observed will result from the interventions imple-
mented plus the way these are used to change practice.
We designed a novel cluster-randomised trial with an a
priori plan to analyse quantitative data, using multilevel
regression models to explore the effects of each interven-
tion on the primary and secondary outcomes, with adjust-
ment for relevant patient-level factors. The study
collected preintervention data in all eight ICUs for
45 weeks. Thereafter, two ICUs were randomised to
receive the DESISTeducation intervention, two were ran-
domised to receive DESIST education plus DESIST
process feedback, two were randomised to receive
DESIST education plus DESIST responsiveness monitor-
ing and two received all three interventions. After an
8-week implementation period, data were collected for a
further 45 weeks. Figure 2 shows the general design and
structure of the trial. We planned to evaluate DESISTedu-
cation using a before-after approach for all eight partici-
pating ICUs; for the DESIST responsiveness monitoring
and DESIST process feedback interventions, we designed
a factorial-type analysis of the four ICUs receiving the
intervention versus four ICUs not receiving that interven-
tion. We chose to include all ICUs in the evaluation of
DESIST education to ensure all participating units
received at least one intervention; this increased ‘buy-in’,
given the high workload involved in patient enrolment
and data collection. Consistent with the recommenda-
tions of the Medical Research Council complex interven-
tion framework14 15 and the CONSORT guidance for
reporting trials of interventions involving multiple ele-
ments,16 we designed a process evaluation that used
mixed qualitative and quantitative approaches to help
understand whether the interventions were implemented
as planned, the barriers to implementation and factors
that worked well/less well. The process evaluation also
captures the user experience of each intervention, which
is important for success and post-study implementation.
DEVELOPMENT AND DESCRIPTION OF THE
INTERVENTIONS USED IN THE TRIAL
DESIST education
Several studies have identiﬁed education and knowledge
as a barrier to successful sedation-analgesia improve-
ment,17 18 together with anxiety relating to patient
wakefulness.5 6 19 This intervention aimed to increase
knowledge and training of nursing and other staff in a
comprehensive consistent manner. A bespoke modular
education package was developed in collaboration with
an NHS provider of web-based interactive educational
materials (LearnPro NHS: http://www.learnpro.co.uk).
This includes in-built assessment to ensure acquisition of
core knowledge across a range of relevant domains.
Core knowledge tests have to be ‘passed’ in order to
complete training successfully. The education package is
available on NHS computers and personal computers/
devices, and typically takes 2–3 h in total to complete.
The nine modules are titled: Why is it important to get
sedation right? assessing sedative state; commonly used
agents in sedation-analgesia; avoiding excessive sedation;
assessing pain and discomfort in ICU; managing agita-
tion; managing delirium; drug withdrawal; and, helping
patients sleep in the ICU. The education package can
be viewed through the following test link: http://
packagemanager.learnprouk.com using the username:
desisttest. The password is: welcome. In the trial, indivi-
duals use unique logins to enable tracking of training
and performance on assessments.
Each ICU developed strategies aimed at achieving
100% rates of completion by ICU nursing staff during
the 2–3 months implementation phase of the trial, with
a minimum target of 80%. Other staff groups were
encouraged to undertake training but this was not man-
dated. Inbuilt systems tracked training completion
within each ICU and fed back data to local trainers.
Individuals completed a questionnaire comprising 10
core knowledge questions prior to undertaking the edu-
cation package; this was repeated >5 months after the
implementation phase and an analysis prespeciﬁed to
assess rates of core knowledge and changes/retention
during the study. The DESIST education package was
freely available to all staff throughout the postinterven-
tion period, along with strategies to use it, as an ongoing
resource developed in each ICU.
DESIST process feedback
Regular visual performance feedback is a well-
established mechanism for driving quality improvement,
which has been effective in the critical care setting,20
particularly in relation to ICU-acquired infection.21 22
Using an iterative development process that included
engagement with clinicians in the participating ICUs,
process control charts were developed to illustrate the
proportion of DESIST care periods with optimum sed-
ation, unnecessary deep sedation, agitation, poor limb
relaxation and poor ventilator synchronisation over
time. These were piloted using data collected during the
preintervention part of the trial. To reduce random vari-
ability, all data for 2-month periods from each ICU were
combined to generate process control Proportion ‘P’
charts illustrating the proportion of DESIST care periods
for which each of the ﬁve sedation-related measures
were present.23 Charts included upper and lower
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warning and control limits, and a mean value for each
ICU using the preintervention data. In addition, prespe-
ciﬁed sedation-related adverse events were collected on
a daily basis by research staff, and used to generate
count ‘G’ charts documenting the numbers of patients
treated without a sedation-related adverse event.
Warning and control limits for these charts were calcu-
lated. For the ICUs randomised to receive sedation
quality feedback, reports of sedation quality were pro-
vided using these charts, and updated every 2 months
during the intervention period, to summarise trends in
sedation-analgesia quality and adverse event rates. ICUs
were provided with strategies to share data from the
reports (including posters and slide-sets), and encour-
aged to integrate these into quality improvement and
other activities. The development and a description of
the process control charts took part in the early part of
the DESIST research programme and have been
described in detail separately.12
DESIST responsiveness monitoring
The Responsiveness monitor is a novel technology devel-
oped collaboratively between GE Healthcare and
Edinburgh University. The concept is to provide a
measure of patient arousal based on continuous fEMG
data collected via frontal electrodes, with the intention
of providing a continuous alert to the potential presence
of excessive sedation. The algorithm utilises the previous
60 min of fEMG data to derive an index, the
Responsiveness Index (RI), calibrated 0–100. The algo-
rithm has been published previously,24 together with
initial clinical validation studies. RI data are further sim-
pliﬁed using a ‘trafﬁc light’ system in which Red RI
values (RI 0–20) are intended to indicate patients with a
higher probability of deep sedation, whereas Amber
values (RI 20–40) and Green values (RI >40) indicate
more frequent arousals and a lower probability of deep
sedation. Validation studies indicated a non-linear correl-
ation/concordance with intermittent clinical sedation
assessments; speciﬁcally, Red values can occur during
sleep and low levels of clinical stimulation, and as a
result of illness-related coma. The system is not designed
for use in patients receiving neuromuscular blocking
drugs. In a proof of concept trial, RI monitoring was
used safely to assist nurse sedation decision-making
when red RI values were present, and was acceptable to
staff.25 Preliminary data suggested that RI monitoring
could decrease the time spent with lower RI values, and
may decrease sedation-analgesia use, especially when the
RI was low early in the ICU stay. The ICUs randomised
to RI monitoring in DESIST were supplied with sufﬁ-
cient monitoring systems to enable the technology to be
used in all enrolled patients, and staff received training
and instruction in the use and interpretation of data.
Figure 2 The general structure of the DESIST trial indicating the preintervention, implementation and postintervention periods in
relation to the quality improvement interventions. The total duration of each period and the timings of qualitative studies to inform
the process evaluation are shown. ICU, intensive care unit.
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The ICUs were encouraged to use RI monitoring
throughout periods of sedation for all enrolled patients,
and nurses were encouraged to review and reduce sed-
ation, when appropriate, if Red RI values were present.
However, no strict protocols were supplied to determine
sedation-analgesia use according to RI data, given that
the correlation between RI value and clinical sedation
status is non-linear.
STUDY POPULATION
We aimed to undertake a system level evaluation, so all
mechanically ventilated, intubated patients were consid-
ered potentially eligible, including patients in whom
mechanical ventilation via an endotracheal tube was
instituted at some time after ICU admission; these
patients were eligible for inclusion from the time intub-
ation and mechanical ventilation began.
Exclusions at the time of screening were patients: (1)
not receiving mechanical ventilation via an endotracheal
tube or a tracheostomy; (2) in whom mechanical ventila-
tion had been discontinued at the time of screening for
study inclusion; (3) in whom discontinuation of mechan-
ical ventilation was anticipated in the next 4 h; (4) in
whom a decision to withdraw active therapy had been
made; (5) in whom consent from a relative or welfare
guardian was not obtained within 48 h of the start of
mechanical ventilation; and (6) in whom the clinician
caring for the patient declined permission for inclusion.
According to the cluster design, the entire ICU agreed
to implement any of the interventions prior to participa-
tion. This was achieved through meetings and presenta-
tions to medical and nursing leads, relevant health
service managers, education teams and quality improve-
ment teams, prior to starting preimplementation base-
line data collection. However, as almost all eligible
patients lacked mental capacity at the time of screening
for consent to participate, the Adults with Incapacity Act
(Scotland; 2000) required consent from a relative/
welfare guardian. To avoid potential selection bias, an
identical approach was used throughout the study
phases and across all ICUs. For the focus groups and
ﬁeld work, ethical approval was provided within the
main trial application. Individual consent from staff
members was not required.
DATA COLLECTION
Demographic and sedation-related data
For all participating patients age, sex, APACHE II score
and admission diagnosis were recorded via the Scottish
Intensive Care Society Audit database (http://www.
sicsag.scot.nhs.uk). Throughout the study, a SQAT was
completed for all DESIST care periods from enrolment
until ICU discharge or death, by the clinical nurse
caring for the patient at the end of each 12 h period of
care. All SQAT forms were collected, and data entered
into the trial database at the Edinburgh Clinical Trials
Unit. In addition, data were collected daily by research
staff in the case record ﬁle to include: cumulative dose
of sedative, analgesic and antipsychotic medication; the
occurrence of predeﬁned sedation-related adverse
events (unplanned removal of nasogastric tube, central
line, arterial line, drain or peripheral line; unplanned
extubation; staff injury; patient injury); mechanical venti-
lation status; timing of extubation; and ICU outcome. At
the end of the study, data to describe duration of mech-
anical ventilation, ICU length of stay, hospital length of
stay, and ICU and hospital mortality, will be extracted
from the Scottish Intensive Care Society Audit database,
which is collected within each ICU using the
Wardwatcher system.
Patient experience data
Sedation practice may inﬂuence patient recall of their
ICU stay, including experience of discomfort, pain,
unpleasant dreams and delusional memories. This may
contribute to longer term psychological morbidity such
as anxiety, depression and post-traumatic stress. Wherever
possible, patients who survived their ICU stay were
approached to complete the following questionnaire-
based measures once mental capacity was regained, pref-
erably close to the time of discharge from hospital:
Impact of Events Scale Revised (IES-R):26 This 22 item
scale is designed to detect post-traumatic symptomatol-
ogy and is suitable for delivery in the hospital period fol-
lowing critical care. Responses can be used to generate
scores for ‘avoidance’, ‘intrusion’ and ‘hyperarousal’
subscales, as well as a total IES-R score.
Intensive Care Experience Questionnaire (ICE-Q):27
This 31 item questionnaire is designed to assess the
patient’s memories of intensive care and perception of
the ICU experience in four domains, namely, ‘awareness
of surroundings’, ‘frightening experiences’, ‘recall of
experience’ and ‘satisfaction with care’.
STUDY PHASES
The exact duration of each phase was uncertain at study
start-up, because the sedation-analgesia quality metrics
were under development and sample size estimations
relied on early recruitment data within the ICUs. The
justiﬁcation for the ﬁnal duration of enrolment is shown
below (see sample size).
Preintervention period
The preintervention period ﬁnally comprised 45 weeks
for each ICU. During this period, no study interventions
occurred and data collected represented baseline prac-
tice for each ICU. We used data during this period, to
estimate sample size for statistical modelling and deter-
mine the duration of patient enrolment for each phase.
Implementation period
The introduction and implementation of the allocated
intervention(s) aimed to be completed during a
2-month period. All ICUs nominated a local champion
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(a co-investigator on the project), who facilitated change
within the ICU and engaged existing clinical and quality
improvement teams. For DESIST education, this com-
prised training at least 80% of nursing staff (target
100%) through completion of the DESIST education
package. For DESIST process feedback, sedation quality
reports plotting data at 2 monthly intervals were sup-
plied for the 45-week preintervention period and a
multidisciplinary stakeholder meeting was organised in
the ICU. Methods for sharing and utilising the sedation
quality process feedback in routine ICU activities were
developed. For DESIST responsiveness monitoring, RI
monitoring systems were provided, with training of core
staff in their use and interpretation, and support during
clinical use was offered.
Postimplementation period
Data continued to be collected for all enrolled patients
during a further 45-week period during which the allo-
cated interventions were used to support
sedation-analgesia practice. For the ICUs allocated to
sedation quality feedback, data were entered into the
trial database in real time and used to generate the sed-
ation quality process feedback reports every 2 months, at
which point charts were updated to include the preced-
ing 2-month period. For the ICUs allocated to RI moni-
toring, RI data were recorded hourly during periods of
monitoring, using the Red, Amber and Green colour
coding. These data were used during the process evalu-
ation to describe the use of the RI technology. All ICUs
received at least one visit from the research team during
the ﬁrst 2–3 months of the postimplementation period
and additional support as required by telephone or
teleconference.
SAMPLE SIZE
We initially estimated that the eight ICUs would admit
≈2900 ventilated patients each year (range 250–750
between ICUs), although many patients would be
excluded due to short ventilation duration. Assuming
40–60% enrolment of ventilated patients would have
provided approximately 1400 patients per year. Baseline
proportions of DESIST care periods with ‘optimum sed-
ation’ were uncertain prior to the study. We estimated
70% rates for the purpose of modelling sample size.
We expected differences between the ICUs, so esti-
mates required to take clustering into account. We ini-
tially modelled study power using ‘best case’ and ‘worst
case’ recruitment scenarios based on recruitment
during the early part of the preintervention period. An
absolute increase in the rate of optimum sedation by
25% from a baseline rate of 70% would be clinically
important and likely to translate into patient beneﬁt. We
assumed power 80%, two-sided signiﬁcance level 5%
and comparison of intervention versus control with a
continuity-corrected χ2 test. To account for clustering
(participants within ICU), a sample size inﬂation factor
1+(m−1)×ICC was applied where m is the cluster size
and ICC the intraclass correlation coefﬁcient. The ICC
was unknown prior to the study; table 1 gives the
primary outcome improvements detectable for a range
of ICC values with numbers of participants ranging from
250 per ICU per study period (1000 per four ICU
cluster) (see table 1(A)) to 66 per ICU per study period
(264 per four ICU cluster) (see table 1(B). These esti-
mates indicated that, although the ICC was uncertain,
we would have sufﬁcient power to detect moderate to
large changes in the primary outcome measure, and
would likely be able to measure effect sizes for the sec-
ondary outcomes with a reasonable degree of precision.
Lower numbers of patients recruited per ICU would
decrease the penalty paid for the clustering in the
design, which offsets the reduction in sample size, such
that lower recruitment rates would have minimal effect
on our study power to detect improvements in rates of
optimum sedation practice.
Based on data during the early part of the preinter-
vention period, we estimated that the smallest ICU
would recruit, on average, 2–3 patients/week, and that
Table 1 ‘best’ and ‘worst’ case scenarios used to estimate the optimum sample size and duration of the preintervention and
postintervention periods in the eight ICUs
Participants
per ICU
Power
(%)
Reference
process rate
(%)
Mean process
rate change
detectable (%)
Base
sample size
per group ICC
Inflation
factor
Inflated sample size
(4 ICUs per analysis
group): participants
per group
(A) ‘Best case scenario’ sample size justification
250 80 70 19.7 74 0.05 13.45 1000
250 80 70 26.2 38 0.10 25.90 1000
250 80 70 29.3 29 0.13 33.37 1000
(B) ‘Worst case scenario’ sample size justification
66 80 70 19.7 74 0.040 3.57 264
66 80 70 26.2 38 0.092 6.95 264
66 80 70 29.3 29 0.125 9.10 264
Inflation factor is 1+(m−1)×ICC, where m=cluster size.
ICU, intensive care unit.
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recruitment for 45 weeks during each of the preinter-
vention and postintervention periods would be expected
to provide ≥100 patients per ICU per study period
(≥400 patients per four ICU group). As the primary ana-
lysis was based on DESIST care periods, rather than indi-
vidual patients, we expected substantially larger numbers
of evaluable data periods for the modelling.
RANDOMISATION
We organised the study so that participating ICUs
started the study in a staggered manner to enable
support by the research team at key stages, notably the
implementation period. Randomised allocation was
revealed to ICUs at the end of the preintervention
period to ensure allocation concealment during baseline
data collection. The eight ICUs were randomised
according to computer-generated random permuted
blocks, stratiﬁed according to the time at which the ICU
started recruitment to the study into ‘early’ (ﬁrst four
ICUs to start recruitment) and ‘late’ (last four ICUs to
start recruitment), in order to balance higher and lower
recruiting sites within each intervention comparison.
Two ICUs were therefore randomised into each of the
following four intervention groups:
Group 1: DESIST education
Group 2: DESIST education plus DESIST process
feedback
Group 3: DESIST education plus DESIST
Responsiveness monitoring
Group 4: DESIST education plus DESIST process feed-
back plus DESIST Responsiveness monitoring.
PROCESS EVALUATION AND QUALITATIVE STUDY
A prespeciﬁed plan recorded compliance with the
planned implementation strategy by local research
implementation teams. The following data were cap-
tured relevant to each of the three interventions as
follows:
1. ‘DESIST education’: the proportion of ICU nursing
staff that completed the DESIST education package
and passed all modular assessments;
2. ‘DESIST process feedback’: the number of process
reports and slide sets provided to the ICUs. The
maximum number of reports, including the imple-
mentation period report, was six;
3. ‘DESIST responsiveness monitoring’: whether formal
training in the use of theRI monitoring occurred
according to a prespeciﬁed training schedule; the
number of enrolled patients who received any period
of RI monitoring; the number of RI data logged by
bedside nurses, based on the data recorded in the
case record ﬁle. The RI data observed in the enrolled
patients will also be described to explore how the
technology was used.
Qualitative data were collected during all phases of
the study. Multiprofessional focus groups were con-
ducted in each ICU prior to the implementation phase,
to understand the current culture of sedation practice.
During the implementation and postimplementation
phases, participant observation was undertaken by the
same researcher (KK) in all ICUs in three distinct time-
lines, to understand the uptake of the interventions and
changes in practice. This was at: the end of the imple-
mentation phase; midway in the postimplementation
phase; at the end of the postimplementation phase. We
also formed multiprofessional focus groups in the ﬁnal
month of the postimplementation phase, in which parti-
cipants reﬂected on the uptake of the intervention(s)
and the changes in sedation practice.
Data from ﬁeld notes from participant observation
and focus groups transcripts were verbatim transcribed
and then checked for accuracy of transcription by the
qualitative researcher and by a member of the research
team in each ICU. Data were entered into NVivo V.10
for Windows software for qualitative analysis (QSR
International, Ltd). For analysis, data will be organised
by ICU setting for coding. An inductive thematic analysis
will be conducted without a predeﬁned theoretical
framework to allow the in-depth exploration and under-
standing of the impact of interventions on sedation
management. Constant comparison will ensure that the
thematic analysis represents all perspectives, and nega-
tive cases will be sought. Validity checking of the coding
includes recoding of data from four ICUs, representative
of each intervention group, by an independent
researcher ( JH). Discordant coding and disagreement
will be resolved by discussion within the wider research
team. To build a valid argument for choosing the
themes, the related literature will be searched to facili-
tate the interpretation of the data.
Primary coding will involve identifying common pat-
terns of experiences with each intervention in each ICU.
All data that relate to the already classiﬁed patterns will
be explored to categorise engagers versus non-engagers
with the interventions; barriers and facilitators to adopt-
ing and implementing the intervention(s) will be
explored, and quality improvement strategies and
changes in sedation practice that occurred will be con-
sidered for each ICU. Patterns of changes in sedation
practice will be compared to the identiﬁed gaps in prac-
tice from the preintervention focus groups for each
ICU. Related patterns will be combined and catalogued
into subthemes. We will compare themes by character-
istics of ICUs (ie, size of ICU, patient case mix, staff
levels). Finally, we will compare themes by combination
of interventions to identify any intervention(s) inter-
action patterns. Comparison of ICUs in relation to
engagement and adoption of the interventions will be
summarised to inform and understand the quantitative
analysis.
OUTCOMES
Study outcomes are shown in box 1. The primary
outcome, and main secondary outcomes, are measures
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of sedation quality. Other secondary outcomes describe
sedative drug use, ICU and hospital outcomes.
Exploratory outcomes will include the measures of ICU
experience recorded among surviving patients after
their discharge from the ICU.
ANALYSIS
The analysis will be based on the intention-to-treat prin-
ciple and will include all ICUs and all consented
patients with available data. The only exception will be
patients admitted with a diagnosis of status epilepticus:
these are rare (about 1% of admissions), require more
complex and individualised sedation management and
could confound the outcome measures of interest in
DESIST. An overall signiﬁcance level of 5% (two-sided)
will be used; an emphasis on reporting 95% CIs in the
estimation of effect sizes will be used given the study
design, and uncertainties about event rates and recruit-
ment. The planned analyses will be performed using
STATA (StataCorp; http://www.stata.com), MLwiN
(University of Bristol; http://www.bristol.ac.uk/cmm/
software/mlwin) and SAS (http://www.sas.com) statis-
tical software.
The following ICU level factors will be used to
describe the patients included within each ICU
(cluster): number and proportion of eligible patients
enrolled in each trial phase; occurrence of each sed-
ation quality outcome in each trial phase; age, gender,
APACHE II score, admission type and ICU admission
diagnosis of patients in each trial phase. Age, sex and
APACHE II score will be used in the modelling to adjust
for differences between ICUs and also changes within
ICUs between the preintervention and postimplementa-
tion periods.
The primary analysis of the binary primary outcome
will be a multilevel generalised linear regression mixed
model that uses outcome as the dependent variable;
ICU, time period (preintervention or postimplementa-
tion) and ICU by time period interaction as the ﬁxed
effects independent variables at the ICU level; and age,
sex and APACHE II score as the ﬁxed effects independ-
ent variables at the admission level. A 3-level multilevel
random intercept model will be ﬁtted using MLwiN,
where DESIST care period is level 1, admission is level 2
and ICU is level 3. Markov Chain Monte Carlo methods
will be used for parameter estimation, and the intraclass
correlation coefﬁcient (ICC) will be reported at level 2
(admission) and level 3 (ICU).
The multilevel model will not in the ﬁrst instance
make formal grouped comparisons between ICUs rando-
mised/not randomised to DESIST responsiveness moni-
toring (R); and between ICUs randomised/not
randomised to DESIST process feedback (P). Similarly,
it will not make a formal grouped comparison between
preintervention and postimplementation to assess the
effect of DESIST education (E). Instead, an OR and
95% CI will be calculated for the preintervention to
Box 1 The outcomes that will be used in the DESIST trial
Primary outcome
Proportion of DESIST care periods with optimum sedation
Secondary sedation quality outcomes
A. ICU level outcomes
A1: Proportion of DESIST care periods with patient agitation
A2: Proportion of DESIST care periods with excessive
sedation
A3: Proportion of DESIST care periods with poor relaxation
A4: Proportion of DESIST care periods with poor ventilator
synchronisation
B. Patient-level sedation outcomes
B1: Number of DESIST care periods with optimum sedation
per mechanically ventilated patient
B2: Number of DESIST care periods with agitation per mech-
anically ventilated patient
B3: Number of DESIST care periods per patient with exces-
sive sedation
B4: Number of DESIST care periods with poor relaxation per
mechanically ventilated patient
B5: Number of DESIST care periods with poor ventilator syn-
chronisation per mechanically ventilated patient
C. Sedation-related adverse events
C1: Proportion of days during mechanical ventilation on
which a sedation-related adverse event occurred*
C2: Proportion of patients receiving mechanical ventilation in
whom a sedation-related adverse event occurred
Sedation, analgesic and antipsychotic drug use
D. Sedative and analgesic drug use
D1: Total use of intravenous sedative drugs per patient (pro-
pofol equivalents†)
D2: Proportion of ICU days on which ≥4000 mg propofol or pro-
pofol equivalents were given (an index of likely deep sedation)
D3: Total use of intravenous analgesic drugs per patient
(alfentanil equivalents†)
D4: Proportion of patients receiving haloperidol
ICU outcomes
E. Duration of mechanical ventilation during index ICU admission
(days)
F. Duration of ICU stay (days)
G. Duration of hospital stay (days)
H. ICU mortality
I. Hospital mortality
Exploratory patient experience outcomes
J. Patient experience and symptoms
J1: Intensive Care Experience questionnaire (ICE-Q) score for
awareness of surroundings, frightening experiences, recall of
experience and satisfaction with care domains
J2: Impact of events scale revised (IES-R) score for: avoid-
ance, intrusion, hyperarousal and total score
Nursing staff knowledge of sedation
K. Change in nursing staff knowledge (based on pretraining vs
5 months post-training test comparisons)
*Unplanned removal of NG tube, central line, arterial line, drain or
peripheral line; unplanned extubation; staff injury; patient injury.
Any combination of the listed adverse events will comprise an
‘adverse event day’.
†A conversion algorithm for all agents used in the ICUs into pro-
pofol and alfentanil equivalents is described in online
supplementary material.
NG, nasogastric tube.
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postimplementation change within each ICU. An OR
value greater than one would indicate an increase in the
proportion of DESIST care periods in which there was
optimum sedation. In the light of the observed variabil-
ity in the OR estimates across ICUs, and informed by
the ﬁndings from the qualitative data, a decision will be
made on whether it is appropriate to perform a pooled
analysis across ICUs to summarise intervention effects
for any of E, R, P or the interaction between R and
P. We plan a priori to make this decision in conjunction
with the members of the independent data monitoring
committee, who will review the individual ICU-level
quantitative data together with the initial ﬁndings of the
process evaluation and qualitative study. This stage has
been included because we anticipate there may be wide
variability in uptake and implementation of the interven-
tions that might make grouped comparison illogical.
The process evaluation, completed by researchers
blinded to quantitative analysis of each ICU (KK and
JH), will inform this decision.
In the event that computational difﬁculties prevent
the successful ﬁtting of the complex three-level multi-
level model described above, we will revert to an alterna-
tive strategy whereby a two-level multilevel model will be
ﬁtted to each ICU separately, in which DESIST care
period is level 1 and admission is level 2. Time period
will be included as an independent variable at ICU level;
age, sex and APACHE II scores will be the independent
variables at the admission level; and a random intercept
will be included for level 2.
Sensitivity analyses
We anticipate that implementation and uptake of the
interventions may not be complete at the end of the
2-month implementation period, and are likely to con-
tinue during the postintervention period. In addition,
the QI process is intended to continue throughout the
postintervention period. We will repeat the analysis
including only postimplementation data recorded in the
ﬁnal 30 weeks of the study, which will assess the effect of
the interventions after a 5–6-month total period of QI
activity.
Secondary outcomes
Binary secondary outcomes (A1, A2, A3, A4; C1; D2;
table 1) will be analysed in the same manner as in the
primary outcome. Binary secondary outcomes measured
at the patient or admission level (C2; H; I; table 1) will
be analysed using a 2-level multilevel generalised linear
model, including the same independent variables as
used in the model for the primary outcome. Continuous
secondary outcomes (D1, D3; table 1) will be analysed
using a 2-level multilevel normal linear model, including
the same independent variables as used in the model
for the primary outcome. Secondary outcomes involving
a count of a number of events (B1, B2, B3, B4, B5) will
be analysed using 2-level multilevel Poisson regression,
including an offset term for the number of eligible care
periods in an admission. The model will contain the
same independent variables as used in the primary
outcome model. A rate ratio and 95% CI will be calcu-
lated for the preintervention to postimplementation
change within each ICU. A rate ratio value greater than
one would indicate an average increase in the outcome
event count per admission. Time-to-event secondary out-
comes (E, F, G) will be analysed using a 2-level multilevel
Cox proportional hazards regression model. The model
will be ﬁtted using a Poisson model in MLwiN by split-
ting follow-up time into as many intervals as there are
events, and will contain the same independent variables
as used in the primary outcome analysis. Larger time
intervals may be used if it becomes too computationally
intensive, which would result in a close approximation
of the Cox model.
A detailed analysis plan was agreed prior to locking
the data base, and is included as online supplementary
material.
COMMENT
The DESIST study uses a novel design and analysis to
evaluate the effectiveness of three contrasting interven-
tions developed to improve sedation quality. The broad
inclusion criteria ensure the population studied will rep-
resent a wide range of critically ill patients, and have
external validity to most settings and healthcare systems
providing ICU care. This approach will decrease the risk
of enrolment bias. The three interventions developed
have differing underpinning rationale. DESIST educa-
tion is a knowledge-based intervention using web-based
learning with inbuilt assessment. We hypothesise that
this intervention may act by directly improving clinical
practice by individual bedside nurses. DESIST process
feedback is an information-based intervention using
novel quality-indicators developed in the research pro-
gramme to feedback performance to the ICU over time
using process control methodology, an approach that
has been successful for decreasing ICU-acquired infec-
tions.21 22 We hypothesise that this approach may drive
quality improvement through regular provision of
detailed performance data, although quality improve-
ment will rely on ICUs generating interventions and
undertaking Plan-Do-Study-Act tests of change. DESIST
responsiveness monitoring will use a novel technology
designed to alert bedside clinical staff to the possibility
of excessive sedation (Red responsiveness number). We
hypothesise that this approach will support nurse
decision-making and decrease the prevalence of exces-
sive sedation, which is associated with adverse patient
outcomes.
Given the absence of agreed methods for quantifying
sedation quality and optimum sedation-analgesia for the
purpose of clinical evaluations, we had to develop mea-
sures of sedation quality speciﬁcally for the trial.12 We
maximised efﬁciency by undertaking part of this work
during the preintervention data collection period.
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Previous sedation trials have focused on metrics such as
duration of mechanical ventilation and ICU stay, where
the trial interventions were designed to minimise sed-
ation use and deep sedation.28–31 These outcomes are
important, but may miss other important outcomes such
as pain, agitation and sedation-related adverse events.
Current guidelines emphasise the need to provide
optimum pain, agitation and delirium management in
addition to avoiding unnecessary deep sedation,1 and
observational studies indicate a high prevalence of
recalled pain and distressing memories among ICU sur-
vivors.11 32 Patients also express preference for deeper
sedation and get greater satisfaction when target sed-
ation ranges are achieved.33 Our primary outcome and
main secondary outcomes speciﬁcally quantify the preva-
lence of overall optimum sedation, as well as measures
of unnecessary deep sedation, agitation and pain/dis-
comfort. Our analytical approach will also explore these
at a system level (ICU level) and at patient level. A limi-
tation of our design is that we will not capture the preva-
lence of delirium, which is associated with adverse
outcomes.1 Delirium measurement requires frequent
clinical assessments by trained staff, but resource con-
straints meant it was not feasible to include this. We con-
sidered including delirium as an outcome measure
within the trial, but our focus was on optimising
sedation-analgesia management. In addition, although
delirium has been associated with adverse outcomes, no
intervention other than optimising sedation practice has
been shown to reduce delirium prevalence.1 By captur-
ing rates of agitation in a systematic manner, we expect
to detect cases of agitated delirium, although part of the
focus of the education package is to highlight that
several factors can cause agitation in the ICU patient. In
addition, by recording the use of haloperidol, the most
widely used drug for treating agitated delirium in our
setting, we expect to capture major changes in pharma-
cological delirium management.
Our modiﬁed cluster design tests the three interven-
tions simultaneously, and uses generalised linear mixed
models to explore treatment effects and interactions.
Advantages of this approach include its efﬁciency, which
is relevant given the complexity and high cost of clinical
trials in critically ill populations. As DESIST is a quality
improvement trial aiming to evaluate three different
interventions simultaneously, we considered this
approach best suited to the research questions. We
could have designed cluster-randomised or step-wedge
trials testing each intervention separately, but this would
have been signiﬁcantly more complex and expensive. An
individual patient parallel randomised design was not
well suited to the system-level interventions.
Disadvantages of our approach included uncertain study
power prior to starting, and the real likelihood of differ-
ing degrees and patterns of uptake of the interventions
between the participating ICUs. By using data during
the early preintervention period, we were able to
optimise sample size and recruitment duration, and will
focus on effect sizes with 95% CIs to describe quantita-
tive ﬁndings. Another potential weakness was our inabil-
ity to blind clinicians from the trial interventions,
increasing the possibility of participation bias. This is
unavoidable in system-level quality improvement
research, which relies on behaviour change. Our design
aimed to reduce the potential importance of participa-
tion bias by the long duration of data collection, the
inclusion of a sensitivity analysis including data from the
ﬁnal 30 weeks, and the use of a bespoke validated
quality assessment tool that used ofﬂine algorithms to
calculate outcomes and blinded these from staff during
the trial. We also planned, a priori, to include a detailed
process evaluation using mixed methods to understand
the impact of the interventions on practice throughout
the recruitment period. These approaches are in
keeping with current recommendations for evaluating
and reporting complex healthcare interventions.14 15 We
recognise that DESIST may not provide deﬁnitive effect-
iveness data, however, it will inform the ongoing devel-
opment of strategies to improve sedation quality. The
methodological approach will also be potentially rele-
vant to other complex intervention research both in crit-
ical care and in other challenging settings.
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